The coupling reaction of 1,2-epoxy-4-cyclohexene with CO2 in the presence of a ZnCl2/nBu4NI catalyst system was shown to provide the naturally occurring cis-cyclohexadiene carbonate. An alternative synthesis of this compound, which was characterized by X-ray structural analysis, was carried out from the cis-diol and triphosgene. Upon utilizing binary or bifunctional (salen)CrX catalysts, this coupling process resulted in the selective formation of completely alternating copolymer of 1,2-epoxy-4-cyclohexene and carbon dioxide. In the case involving the binary chromium(III)/onium salt catalyst, small quantities of both the cis and trans cyclic carbonates were also produced. The (salen)CoDNP/PPNDNP (DNP = 2,4-dinitrophenolate) catalyst system was most effective at producing high molecular weight copolymer with 100% selectivity. The T g of this polymer (M n = 35.9 kDa) was determined to be 123 °C, which is higher than the T g (116 °C) of the corresponding saturated copolymer. Depolymerization of poly(cyclohexadiene carbonate) to trans-cyclohexadiene carbonate occurred slowly and cleanly at 110 °C following deprotonation of the terminal hydroxyl group. The trans-cyclohexadiene carbonate was independently synthesized via the carbonylation of the trans-diol with ethyl chloroformate. The hydrophobic 1,2-epoxy-4-cyclohexene/CO2 derived copolymer was modified by the quantitative addition of thioglycolic acid by way of the thiol–ene click reaction to afford an amphiphilic copolymer. Upon deprotonation of this functionalized polycarbonate with ammonium hydroxide, the production of a water-soluble polymeric material was achieved which displayed a T g of 120 °C.

The lipid composition of cellular membranes is dynamic and undergoes remodelling affecting biophysical properties, such as membrane fluidity, which are critical to biological function. Here, we introduce an optical approach to manipulate membrane fluidity based on exogenous synthetic fatty acid with an azobenzene photoswitch, termed FAAzo4. Cells rapidly incorporate FAAzo4 into phosphatidylcholine (PC), the major phospholipid in mammalian cells, in a concentration- and cell type-dependent manner. This generates photoswitchable PC analogs (AzoPC), which are predominantly located in the endoplasmic reticulum (ER). Irradiation causes a rapid photoisomerization that increases membrane fluidity with high spatiotemporal precision. We use these ‘PhotoCells’ to study the impact of membrane mechanics on protein export from the ER and demonstrate that this two-step process has distinct membrane fluidity requirements. Our approach represents an unprecedented way of manipulating membrane fluidity in cellulo and opens novel avenues to probe roles of fluidity in a wide variety of biological processes.

Oxytocin is a neuropeptide critical for maternal physiology and social behavior, and is thought to be dysregulated in several neuropsychiatric disorders. Despite the biological and neurocognitive importance of oxytocin signaling, methods are lacking to activate oxytocin receptors with high spatiotemporal precision in the brain and peripheral mammalian tissues. Here we developed and validated caged analogs of oxytocin which are functionally inert until cage release is triggered by ultraviolet light. We examined how focal versus global oxytocin application affected oxytocin-driven Ca2+ wave propagation in mouse mammary tissue. We also validated the application of caged oxytocin in the hippocampus and auditory cortex with electrophysiological recordings in vitro, and demonstrated that oxytocin uncaging can accelerate the onset of mouse maternal behavior in vivo. Together, these results demonstrate that optopharmacological control of caged peptides is a robust tool with spatiotemporal precision for modulating neuropeptide signaling throughout the brain and body.

Dipyrrolidylmethane, CH 2 (pyr) 2 , and dipiperidylmethane, CH 2 (pip) 2 , are synthesized via the condensation of their respective secondary amine precursors and dichloromethane at room temperature in the absence of light. Their use as chelating ligands is shown by the isolation and complete characterization of [CH 2 (pyr) 2 ]Mo(CO) 4 and [CH 2 (pip) 2 ]-Mo(CO) 4 complexes. X-ray analysis reveals the methylene bis(cycloamines) to possess a sharp bite angle between 61°and 63°and a strong steric impact on the surrounding carbonyl ligands as a result of their ring conformations.

Limited guidance exists for dosing melphalan for autologous stem cell transplantation (ASCT) in the obese patient population, because the current literature reports conflicting clinical outcomes between obese and nonobese patients. In 2014, the American Society for Blood and Marrow Transplantation published conditioning chemotherapy dosing guidelines for obese patients and recommended dosing of melphalan using actual body weight (ABW) in the body surface area calculation. The practice at Barnes-Jewish Hospital has consistently been to dose melphalan using adjusted body weight (AdBW), with a 20% correction when a patient weighs ≥120% of his or her ideal body weight (IBW). The purpose of this study was to compare outcomes of melphalan ASCT in patients with multiple myeloma between obese (≥120% IBW) and nonobese (<120% IBW) populations. This retrospective, single-center study included adult patients with multiple myeloma undergoing first ASCT with melphalan conditioning between January 2009 and December 2012. Patient demographic data, transplantation characteristics, and clinical outcomes were collected. The primary outcome was 3-year event-free survival (EFS). Secondary outcomes included response at 100 days post-transplantation, 3-year overall survival, treatment-related mortality (TRM), time to neutrophil engraftment, and hospital length of stay (LOS). To ensure that melphalan dosage adjustment in the obese population did not impact efficacy, the primary outcome was assessed using a noninferiority design, with a predetermined noninferiority margin of 7%. Assuming a 70% 3-year EFS in the nonobese population, a noninferiority margin of 7%, a power of 80%, and an α value of .05, an analysis of 280 patients was required. A total of 270 patients, including 171 (63%) obese patients and 99 (37%) nonobese patients, met our inclusion criteria. Baseline characteristics were well matched between the 2 cohorts, including high-risk cytogenetics, disease severity at diagnosis, and use of maintenance therapy, with the only detectable differences related to weight itself. The 3-year EFS was 41% for the total cohort, with fewer events occurring in the obese cohort compared with the nonobese cohort (51% versus 40%; P = .0025). The 95% lower confidence limit established noninferiority. High-risk cytogenetics, disease severity at diagnosis, and therapy response pre- and post-ASCT were all associated with significantly shorter EFS. No between-group differences in TRM, time to engraftment, or hospital LOS were noted. This retrospective, single-center study found that using AdBW to dose melphalan in obese patients was not inferior to the nonobese population in terms of 3-year EFS. This study adds to the limited evidence on melphalan dosing and suggests that transplantation efficacy is not affected by AdBW dosing in obese patients. Further studies are needed to provide additional insight into the pharmacokinetic differences and best dosing practices for obese patients.